Seer’s Board Keeps Saying No — But the Real Question Is Whether $2.40 Is an Insult or an Intervention
Seer's board has now rejected three unsolicited bids from the Radoff-JEC Group. At $2.40/share, the offer exposes a brutal...
Jupiter Neurosciences’ $100M ALA-002 Bet Is a Regulatory Arbitrage Play, Not a Science Story
Jupiter Neurosciences (JUNS) just licensed ALA-002, a Novel Chemical Entity MDMA, for $100M+—here's why the NCE status matters more...
The Junk-to-Grade Playbook: Why Teva’s Upgrade Is a Signal, Not a Story
Teva's BBB- upgrade from Fitch on May 18 signals a new M&A-ready posture—and reveals a playbook other over-leveraged pharma...
Regeneron’s Fianlimab Flop Rewrites the LAG-3 Playbook — and Bristol-Myers Just Got Luckier
Regeneron's Phase 3 fianlimab trial misses in first-line melanoma, threatening a key pipeline asset and handing Opdualag a competitive...
The GLP-1 Wars Are Over — The Incretin Platform Wars Have Begun
Orforglipron's 72-week Phase 3 data, SURMOUNT-5's head-to-head verdict, and Roche's oral small molecule push signal a $87B market restructuring...
BMS Just Paid to Solve Its Patent Cliff With Someone Else’s Pipeline
Bristol Myers Squibb's 13-program deal with Hengrui Pharma is the clearest signal yet that Western pharma's next growth decade...
Innovent’s Triple Breakthrough Play: IBI363 Just Became the Most Dangerous Asset in Immuno-Oncology’s Coldest Corner
Innovent's IBI363 scores its third NMPA Breakthrough Therapy Designation—this time for MSS/pMMR colorectal cancer, the tumor type that killed...
The FDA Just Validated a $1.6 Billion Platform — and the Real Winner Isn’t Pfizer
FDA's May 2026 approval of Veppanu, the first PROTAC drug, validates targeted protein degradation as a platform — and...
argenx’s $1.3 Billion Quarter Proves FcRn Dominance — Now the Real Test Begins
argenx hit $1.3B in Q1 2026 product sales, up 63% YoY. With two VYVGART label expansions pending and empasiprubart...
Madrigal’s $1 Billion PNPLA3 Bet Rewrites the MASH Playbook — And Leaves Competitors Chasing a Genetically Defined Market
Madrigal licenses ARO-PNPLA3 from Arrowhead for up to $1B, targeting a PNPLA3 mutation affecting ~30% of F2–F3 MASH patients,...